journal
Journal For International Medical Graduates
Journal For International Medical Graduates
California Institute of Behavioral Neurosciences and Psychology
US
https://www.cibnp.com
2832-9864
29
Articles
Role of TP53 Gene Mutations in the Pathogenesis of Colorectal Carcinoma
Asmaa Muazzam
Muazzam
Asmaa
asmaa.muazzam@jimgs.com
Chandani Hamal
Hamal
Chandani
chandani.hamal@jimgs.com
Lakshmi Sai Deepak Reddy
Sai Deepak Reddy
Lakshmi
lakshmi.sai.deepak.reddy@jimgs.com
Godfrey Tabowei
Tabowei
Godfrey
godfrey.tabowei@jimgs.com
Greeshma Nihitha Gaddipati
Nihitha Gaddipati
Greeshma
greeshma.nihitha.gaddipati@jimgs.com
Maria Mughal
Mughal
Maria
maria.mughal@jimgs.com
Mohammed Alzubaidee
Alzubaidee
Mohammed
mohammed.alzubaidee@jimgs.com
Raga Sruthi Dwarampudi
Sruthi Dwarampudi
Raga
raga.sruthi.dwarampudi@jimgs.com
Sheena Mathew
Mathew
Sheena
sheenaalvin@gmail.com
Sumahitha Bichenapally
Bichenapally
Sumahitha
sumahitha.bichenapally@jimgs.com
Vahe Khachatryan
Khachatryan
Vahe
vahe.khachatryan@jimgs.com
California Institute of Behavioral Neurosciences and Psychology (United States)
https://ror.org/01ytd2n62
13
09
2022
Received: 1392022
Copyright (c) 2022 Journal For International Medical Graduates
2022
Journal For International Medical Graduates
Molecular pathogenesis
p53 oncogene
tumor suppressor gene
colorectal cancer
tp53 mutations
oncogenesis
production-ready-file-url
[
Brainy quote- Woody Harrelson. https://www.brainyquote.com/quotes/woody_harrelson _555536?src=t_colon.
]
[
Jemal A, Freddie Bray, Melissa M. Center, Jacques Ferlay, Elizabeth Ward, David Forman : Global cancer statistics. CA Cancer J Clin. 2011, 61(2):69-90. 10.3322/caac.20107
]
[
Torre LA, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal : Global cancer statistics, 2012. CA Cancer J Clin. 2015, 65:87-108. 10.3322/caac.21262
]
[
Markowitz SD, Bertagnolli MM: Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009, 361:2449-2460. 10.1056/NEJMra0804588
]
[
Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011, 6:479-507. 10.1146/annurev-pathol-011110-130235
]
[
Matano M, Date S, Shimokawa M, et al.: Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015, 21:25662. 10.1038/nm.3802
]
[
Al-Sukhni W, Aronson M, Gallinger S.: Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008, 88:819-844. 10.1016/j.suc.2008.04.012
]
[
McMurray HR, Sampson ER, Compitello G, et al.: Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature. 2008, 7198:1112-6. 10.1038/nature06973
]
[
Russo A, Bazan V, Iacopetta B, David Kerr, Thierry Soussi, Nicola Gebbia: The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment.. J Clin Oncol. 2005, 23:7518-7518. 10.1200/JCO.2005.00.471
]
[
Glebov OK, Rodriguez LM, Nakahara K, et al.: Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev. 2003, 12:755- 762.
]
[
Missiaglia E, Jacobs B, D'Ario G, et al.: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014, 25:1995- 2001. 10.1093/annonc/mdu275
]
[
Soong R, Powell B, Elsaleh H, et al.: Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer. 2000, 36:2053- 2060. 10.1016/S0959-8049(00)00285-9
]
[
Lawrence MS, Stojanov P, Mermel CH, et al.: Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014:495-501. 10.1038/nature12912
]
[
Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 2005, 24:2899-2908. 10.1038/sj.onc.1208615
]
[
Bond GL, Hu W, Bond EE, et al.: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004, 119:591. 10.1016/j.cell.2004.11.022
]
[
Candi E, Agostini M, Melino G, Bernassola F: How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat. 2014, 35(6):702-714. 10.1002/humu.22523
]
[
Mandinova A, Lee SW: The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med. 2011:3. 10.1126/scitranslmed.3001366
]
[
Soussi, T, Béroud, C.: Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat. 2003, 21:192-200. 10.1002/humu.10189
]
[
Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al.: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol. 2010, 21:772-780. 10.1093/annonc/mdp383
]
[
Nehls O, Okech T, Hsieh CJ, et al.: Studies onp53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br. J. Cancer. 2007, 96:1409-1418. 10.1038/sj.bjc.6603728
]
[
Allegra CJ, Paik S, Colangelo LH, et al.: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol. 2003, 21:241-250. 10.1200/JCO.2003.05.044
]
[
Li T, Kon N, Jiang L, et al.: Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and Senescence. Cell. 2012, 149:1269-1283. 10.1016/j.cell.2012.04.026
]
[
Ahnen D.J., Wade S.W., Jones W.F., et al.: The increasing incidence of young-onset colorectal cancer: A call to action. Mayo Clin. Proc. 2014;89: 216-224. 10.1016/j.mayocp.2013.09.006
]
[
Patel P, De P.: Trends in colorectal cancer incidence and related lifestyle risk factors in 15-49-year-olds in Canada, 1969-2010. Cancer Epidemiol. 2016, 42:90-100. 10.1016/j.canep.2016.03.009
]
[
Ferrari P., Jenab M., Norat T., et al.: Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int. J. Cancer. 2007;121: 2065-2072. 10.1002/ijc.22966
]
[
Park J., Morley T.S., Kim M., Clegg D.J., Scherer P.E.: Obesity and cancer-mechanisms underlying tumour progression and recurrence. Nat. Rev. Endocrinol. 2014:455-465. 10.1038/nrendo.2014.94
]
[
Zehir A, Benayed R, Syed A, et al.: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017, 23:703-713. 10.1038/nm.4333
]
[
Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, Olivier M.: TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016, 37:865-876. 10.1002/humu.23035
]
[
Wolf D, Rotter V: Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. Usa. 1985, 82:790-794. 10.1073/pnas.82.3.790
]
[
Muller, PA, Vousden, KH: Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014, 25:304-317. 10.1016/j.ccr.2014.01.021
]
[
Donehower LA, Harvey M, Slagle BL, McArthur MJ., Montgomery Jr C A, Janet S. Butel J S, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992, 356:215-221. 10.1038/356215a0
]
[
Aschauer L, Muller PA: Novel targets and interaction partners of mutant p53 Gain-Of-Function. Biochem Soc. Trans. 2016;44: 460-466. 10.1042/BST20150261
]
[
Oren M, Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107. 10.1101/cshperspect.a001107
]
[
Zhu J, Sammons MA, Donahue G, et al.: Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015, 525:206-211. 10.1038/nature15251
]
[
Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks M A, Shih L M, Kurman R J: Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
]
[
Shangary S, Wang S: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 2009, 49:223-41. 10.1146/annurev.pharmtox.48.113006.094723
]
[
Momand J, Jung D, Wilczynski S, Niland J: The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26:3453-3459. 10.1093/nar/26.15.3453
]
[
Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420:25-27. 10.1016/s0014-5793(97)01480-4
]
[
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler K W, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993, 362:857-860. 10.1038/362857a0
]
[
Thut CJ, Goodrich JA, Tjian R.: Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 1997, 11:1974-1986. 10.1101/gad.11.15.1974
]
[
Barak Y, Gottlieb E, Juven-Gershon T, Oren M: Regulation of mdm2 expression by p53: alternative promoters produce transcripts with non-identical translation potential. Genes Dev. 1994, 8:1739. 10.1101/gad.8.15.1739
]
[
Poyurovsky MV, Katz C, Laptenko O, et al.: The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 2010, 17:982-989. 10.1038/nsmb.1872
]
[
Nakamura S, Roth JA, Mukhopadhyay T.: Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol. 2000, 20:9391-9398. 10.1128/MCB.20.24.9391-9398.2000
]
[
Fang S, Jensen JP, Ludwig RL, Vousden K H, Weissman A M : Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000, 275:8945-51. 10.1074/jbc.275.12.8945
]
[
Xu GW, Mawji IA, Macrae CJ, et al.: A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis. 2008, 13:413-22. 10.1007/s10495-007-0175-4
]
[
Laptenko O, Tong DR, Manfredi J, Prives C: The tail that wags the dog: how the disordered C-terminal domain controls the transcriptional activities of the p53 tumor-suppressor protein. Trends Biochem Sci. 2016, 41:1022-34. 10.1016/j.tibs.2016.08.011
]
[
Elabd S, Meroni G, Blattner C.: TRIMming p53′s anticancer activity. Oncogene. 2016, 35:5577-84. 10.1038/onc.2016.33
]
[
Ahuja N, Sharma AR, Baylin SB: Epigenetic therapeutics: a new weapon in the war against cancer. Annu Rev Med. 2016, 67:73-89. 10.1146/annurev-med-111314-035900
]
[
Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T, Tsurimot T : CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem. 2008, 283:29045-29052. 10.1074/jbc.M806045200
]
[
Wang Y, Wen M, Kwon Y : CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014, 74:520-531. 10.1158/0008-5472.CAN-13-2182
]
[
Banks D, Wu M, Higa LA, et al.: L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/ DDB1 complexes. Cell Cycle. 2006, 5:1719-1729. 10.4161/cc.5.15.3150
]
[
Sundas Fayyaz, Zeeshan Javed, Rukset Attar, Ammad Ahmad Farooqi, Ilhan Yaylim, Aamir Ahmad: MicroRNA regulation of TRAIL mediated signaling in different cancers: Control of micro steering wheels during the journey from bench-top to the bedside. Semin Cancer Biol. 2019, 58:56-64. 10.1016/j.semcancer.2019.01.007
]
[
Raimo M, Orso F, Grassi E, et al.: miR-146a Exerts Differential Effects on Melanoma Growth and Metastatization. Mol Cancer Res. 2016;14: 548-562. 10.1158/1541-7786.MCR-15-0425-T
]
[
Sathyanarayanan A, Chandrasekaran KS, Karunagaran D.: microRNA-146a inhibits proliferation, migration and invasion of human cervical and colorectal cancer cells. Biochem Biophys Res Commun. 2016;480: 528-533. 10.1016/j.bbrc.2016.10.054
]
[
Ryan KM, Phillips AC, Vousden KH: Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13: 332-337. 10.1016/S0955-067400216-7
]
[
Li XL, Zhou J, Chen ZR, Chng WJ : P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 2015, 21:84-93. 10.3748/wjg.v21.i1.84
]
[
Van Cutsem E, Kohne CH, Lang I, et al.: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011, 29:2011-9.10.1200/JCO.2010.33.5091
]
[
Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 1996, 87:159-70. 10.1016/s0092-8674(00)81333-1
]
[
Iacopetta B: TP53 mutation in colorectal cancer. Hum Mutat. 2003, 21:271-276. 10.1002/humu.10175
]
[
Imamura Y, Morikawa T, Liao X, et al.: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012, 18:4753-4763. 10.1158/1078-0432
]
[
Parada LF, Land H, Weinberg RA, Wolf D, Rotter V: Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 1984, 312:649-51. 10.1038/312649a0
]
[
Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P: Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. Mutagenesis. 2012, 27:211-8. 10.1093/mutage/ger067
]
[
Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ: The regulation of AMPK beta1. TSC2. and PTEN expression by p53: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67:3043-53. 10.1158/0008-5472.CAN-06-4149
]
[
Lyu Y, Lou J, Yang Y, et al.: Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. . Leukemia. 2017, 31:2543-2551. 10.1038/leu.2017.116
]
[
Miyata Y, Kumagai K, Nagaoka T, et al.: Clinicopathological significance and prognostic value of Wilms’ tumor gene expression in colorectal cancer. Cancer Biomark. 2015, 15:789-97. 10.3233/CBM-150521
]
[
Oji Y, Yamamoto H, Nomura M, et al.: Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 2003, 94:712-17. 10.1111/j.1349-7006.2003.tb01507.x
]
[
Zhang R, Xu GL, Li Y, et al.: The role of insulin-like growth factor 1 and its receptor in the formation and development of colorectal carcinoma. J Int Med Res. 2013, 41:1228-35. 10.1177/0300060513487631
]
[
Han L, Zhang GF, Cheng YH, Zhao QC: Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer. Jpn J Clin Oncol. 2016, 46:1127-34. 10.1093/jjco/hyw137
]
[
Keku TO, Sandler RS, Simmons JG, et al.: Local IGFBP-3 mRNA expression. apoptosis and risk of colorectal adenomas. BMC Cancer. 2008, 8:143. 10.1186/1471-2407-8-143.
]
[
Peters G, Gongoll S, Langner C, et al.: IGF-1R. IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Archiv. 2003, 443:139-45. 10.1007/s00428-003-0856-5
]
[
Shiratsuchi I, Akagi Y, Kawahara A, et al.: Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. Anticancer Res. 2011, 31:2541-45.
]
[
Hammel P, Leroy-Viard K, Chaumette M.T, et al.: Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. International Journal of Cancer. 1999;81(5): 712-718. 10.1002/81:5<712. 0:2-0. 10.1002/(SICI)1097-0215(19990531)81:5<712::AID-IJC7>3.0.CO;2-0
]
[
Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K: Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1991, 6:1313-1318.
]
[
Pedersen JW, Dawnay A, Burnell M, et al.: Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer. 2013:107-14. 10.1038/bjc.2012.517
]